Table 1.
Patients demographics and initial clinical characteristics
| PCI Not Received (N=44) |
PCI Received (N=41) |
Total (N=85) |
p value | |
|---|---|---|---|---|
| Arm | 1.0000 | |||
| Sunitinib | 23 (52.3%) | 21 (51.2%) | 44 (51.8%) | |
| Placebo | 21 (47.7%) | 20 (48.8%) | 41 (48.2%) | |
| Age (years) | 0.1694 | |||
| Median | 62.5 | 58.0 | 60.0 | |
| Range | (39.0–77.0) | (44.0–72.0) | (39.0–77.0) | |
| Sex | 0.8291 | |||
| Male | 19 (43.2%) | 19 (46.3%) | 38 (44.7%) | |
| Female | 25 (56.8%) | 22 (53.7%) | 47 (55.3%) | |
| ECOG Performance Status | 0.4785 | |||
| 0 | 22 (50.0%) | 15 (36.6%) | 37 (43.5%) | |
| 1 | 16 (36.4%) | 18 (43.9%) | 34 (40.0%) | |
| 2 | 6 (13.6%) | 8 (19.5%) | 14 (16.5%) | |
| Best response to chemotherapy | 0.6388 | |||
| CR | 2 (4.5%) | 3 (7.3%) | 5 (5.9%) | |
| PR | 37 (84.1%) | 36 (87.8%) | 73 (85.9%) | |
| Stable | 5 (11.4%) | 2 (4.9%) | 7 (8.2%) | |
| Grade 3+ AEs from chemotherapy | 34 (77.3%) | 29 (70.7%) | 63 (74.1%) | 0.6213 |
PCI, prophylactic cranial irradiation; ECOG, Eastern Cooperative Oncology Group; CR, complete response; PR, partial response; AE: adverse event.